Cancer treatment and research communications最新文献

{"title":"Combined single cell and spatial transcriptome analysis reveals hedgehog pathway-related genes as potential therapeutic targets for cervical cancer","authors":"Jing Zheng ,&nbsp;Miaomiao Dou ,&nbsp;Zhenzhen WU ,&nbsp;Chunjie Zhang ,&nbsp;Bo Yang ,&nbsp;Zhijie Liu ,&nbsp;Min Zhang ,&nbsp;Fang Wang","doi":"10.1016/j.ctarc.2024.100841","DOIUrl":"10.1016/j.ctarc.2024.100841","url":null,"abstract":"<div><p>Cervical cancer (CC) remains one of the most common and deadly malignancies among women worldwide, with exceptionally high morbidity and mortality rates. The aberrant activation of the hedgehog pathway is intimately associated with tumor development and progression. Nevertheless, the potential therapeutic targets within the hedgehog pathway in CC have yet to be clearly identified. In this study, we conducted an in-depth investigation of hedgehog pathway-related genes in CC, integrating single-cell sequencing data and spatial transcriptomics. Utilizing a comprehensive scoring algorithm, we identified that myofibroblasts within CC tissue exhibit a highly enriched hedgehog pathway. Our analysis of the myofibroblast development process revealed that MYH9 plays a crucial role. Further exploration using spatial transcriptome data allowed us to delve into the role of MYH9 in myofibroblasts. We discovered that MYH9-negative and MYH9-positive myofibroblasts display distinct profiles. Validation using extensive transcriptome data demonstrated that a high infiltration of MYH9-positive myofibroblasts is a risk factor for CC patients, significantly impacting prognosis and immunotherapeutic efficacy. Our study provides unique insights into the relationship between CC and the hedgehog pathway, offering new directions for cancer treatment strategies.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100841"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000534/pdfft?md5=5683605534cdeb8e806d0fbddc2c4085&pid=1-s2.0-S2468294224000534-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring sex difference in the risk factors and prognosis of inoperable lung cancer","authors":"Muhammad Rafiqul Islam ,&nbsp;Syeda Masuma Siddiqua ,&nbsp;Golam Rabbani ,&nbsp;Salman Bashar Al Ayub ,&nbsp;Rashedul Islam ,&nbsp;Beauty Saha ,&nbsp;Nazrina Khatun ,&nbsp;Mohammad Hasan Shahriar ,&nbsp;Mohammad Rocky Khan Chowdhury ,&nbsp;Sheikh M Alif ,&nbsp;Md Nazmul Karim","doi":"10.1016/j.ctarc.2024.100848","DOIUrl":"10.1016/j.ctarc.2024.100848","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer remains a leading cause of cancer-related deaths globally, with increasing incidence among females. Sex differences in lung cancer risk and outcomes are influenced by various factors, including biological characteristics. In Bangladesh, where lung cancer mortality rates are high, patients often present at advanced stages. However, real-time data on sex-specific survival outcomes for inoperable lung cancer in Bangladesh is lacking.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed patients with inoperable lung cancer at the National Institute of Cancer Research and Hospital in Dhaka, Bangladesh, from 2018 to 2019. Patient demographics and clinical parameters were assessed, with survival tracked until June 2020. Statistical analyses included descriptive statistics, Chi-square tests, <em>t</em>-tests, Kaplan-Meier curves, and multivariable Cox regression models.</div></div><div><h3>Results</h3><div>Females were diagnosed at a younger age (55.3 ± 12.7 vs 60.5 ± 10.2 years, <em>p</em> &lt; 0.001) and had higher comorbidity rates (36.2 %, <em>p</em> = 0.004). Males had higher smoking rates, while females used more smokeless tobacco. Adenocarcinoma was more prevalent in females (47.2 %) and squamous cell carcinoma in males (42.7 %). After adjusting for various factors, females showed a significant survival advantage (median 16 vs 12 months), particularly in adenocarcinoma (HR: 0.64, 95 %CI:0.46–0.90, <em>p</em> = 0.01) and squamous cell carcinoma (HR: 0.52, 95 %CI:0.32–0.85, <em>p</em> = 0.009). Females also demonstrated better survival when receiving supportive care, chemotherapy, or radiotherapy alone but not in combined therapy. Older males (&gt;70), illiterate, smokers, and those with comorbidities had a poor prognosis compared to females.</div></div><div><h3>Conclusion</h3><div>This study reveals significant sex-based differences in inoperable lung cancer patients in Bangladesh. Despite earlier diagnosis and higher comorbidities, females demonstrated better survival rates, particularly in adenocarcinoma and squamous cell carcinoma. These findings highlight the need for sex-specific approaches in lung cancer management to improve patient outcomes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100848"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailoring treatment for locally advanced rectal cancer","authors":"Laudy Chehade,&nbsp;Kristel Dagher,&nbsp;Ali Shamseddine","doi":"10.1016/j.ctarc.2024.100847","DOIUrl":"10.1016/j.ctarc.2024.100847","url":null,"abstract":"<div><div>The management of locally advanced rectal cancer (LARC) requires personalized treatment to improve outcomes and maintain quality of life. This narrative review examines the recent developments in management, focusing on non-operative management, radiotherapy choices or omission, chemotherapy sequencing, and the role of immunotherapy and brachytherapy boost. Non-operative management can be an option for select patients, and the use of long-course chemoradiation (LCCRT) with consolidation chemotherapy or brachytherapy boost has been shown to enhance rectal preservation rates. For patients requiring surgery, the choice between LCCRT and SCRT depends on the risk of local recurrence and patient preferences. MSI-high LARC patients benefit significantly from single-agent immunotherapy, and early clinical trials show promising results for the application of immunotherapy in MSS tumors. By stratifying patients based on individual and tumor risk factors, clinicians can tailor treatment plans to improve oncologic outcomes and quality of life for patients with LARC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100847"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Providers’ knowledge about and barriers to lung cancer screening","authors":"Jeffrey J. Quezada ,&nbsp;Axs R. Avenido ,&nbsp;Stephanie Jia ,&nbsp;Arsanyous Bernaba ,&nbsp;Sabrina Nguyen ,&nbsp;Shayan S. Gharagozlou ,&nbsp;Tan Q. Nguyen ,&nbsp;Hari Keshava ,&nbsp;Gelareh Sadigh","doi":"10.1016/j.ctarc.2024.100850","DOIUrl":"10.1016/j.ctarc.2024.100850","url":null,"abstract":"<div><h3>Objective</h3><div>Low dose computed tomography (LDCT) for lung cancer screening (LCS) is underutilized despite its demonstrated mortality benefit compared to chest radiography. Our study aimed to assess knowledge about LCS and barriers to ordering LDCT from the viewpoint of primary care and pulmonology providers in academic and community settings.</div></div><div><h3>Methods</h3><div>Providers of various specialties (pulmonology, family medicine, internal medicine, geriatric medicine) who were practicing in Southern California and provided care to patients aged 50 or more were asked to complete a 10-minute survey to assess knowledge about LCS criteria, and barriers to the use of LDCT scan screening. Knowledge scores were calculated for each respondent based on their responses to 9 questions based on Centers for Medicare and Medicaid Services eligibility criteria with a total score range from 0 to 9 points.</div></div><div><h3>Results</h3><div>32 eligible providers completed the survey, of which none correctly identified all CMS eligibility criteria. Average knowledge score was 6.6 ± 1.1 and did not significantly differ based on practice setting, training level, or years of practice. Common barriers to utilization of LDCT included inaccurate smoking history in the medical record (56.2 %), failure of the medical record to notify providers of eligible patients (43.7 %), and concerns about financial cost of downstream tests after a positive scan (38.7 %).</div></div><div><h3>Conclusions</h3><div>Suboptimal provider knowledge of LDCT criteria may contribute to LCS underutilization. Improvement of educational resources for providers and augmentation of EMR smart tools to update documented smoking histories and notify providers of eligible patients may improve the rate of LCS.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100850"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The status of serum 25(OH)D levels is related to breast cancer","authors":"Mohammad Momivand ,&nbsp;Mahta Razaghi ,&nbsp;Farshid Mohammadi ,&nbsp;Edris Hoseinzadeh ,&nbsp;Roya Najafi-Vosough","doi":"10.1016/j.ctarc.2025.100870","DOIUrl":"10.1016/j.ctarc.2025.100870","url":null,"abstract":"<div><h3>Aim</h3><div>Breast cancer is the second most common cancer among women and the leading cause of cancer-related mortality in this population. Numerous factors have been identified as either risk factors or protective factors for breast cancer. However, the role of Vitamin D (Vit. D) in breast cancer remains contentious, with conflicting findings in the literature. The present study aimed to compare serum Vit. D levels between women with and without breast cancer.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 40 women diagnosed with breast cancer, referred to the Mahdia Hamadan Radiotherapy Center in 2022. These participants were matched with 40 age- and Vit. D serum level-matched women without breast cancer. Serum Vit. D levels were measured using the ELISA method. Statistical analysis was performed using SPSS version 26, with a significance threshold set at a 95% confidence level.</div></div><div><h3>Results</h3><div>The mean ± standard deviation of serum Vit. D levels in women with and without breast cancer were 31.9 ± 28.27 ng/mL and 37.98 ± 15.89 ng/mL, respectively (P = 0.024). The prevalence of Vit. D insufficiency was 50% in the breast cancer group and 27.5% in the control group, while 50% of the breast cancer group and 72.5% of the control group had sufficient Vit. D levels (P = 0.008). In women with breast cancer, lower Vit. D levels were significantly associated with lower educational (P &lt; 0.001), economic (P &lt; 0.001), and social status (P &lt; 0.001). A weak positive correlation was observed between serum Vit. D levels and patient age (r = 0.162, P = 0.152).</div></div><div><h3>Conclusion</h3><div>The significant difference in serum Vit. D levels between women with and without breast cancer suggests that Vit. D deficiency may be associated with breast cancer risk. These findings support the hypothesis that improving Vit. D status in women could potentially reduce the incidence of breast cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100870"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis","authors":"Louis-Emmanuel Chriqui ,&nbsp;Etienne Abdelnour-Berchtold ,&nbsp;Edoardo Zanfrini ,&nbsp;Severine Devesa-Perez ,&nbsp;Michel Gonzalez ,&nbsp;Thorsten Krueger ,&nbsp;Kim Ellefsen ,&nbsp;Alice Destaillats ,&nbsp;David Bonnet ,&nbsp;Martin Hübner ,&nbsp;Hasna Bouchaab ,&nbsp;Michal Bassani-Sternberg ,&nbsp;Solange Peters ,&nbsp;Sabrina Cavin ,&nbsp;Jean Y Perentes","doi":"10.1016/j.ctarc.2024.100858","DOIUrl":"10.1016/j.ctarc.2024.100858","url":null,"abstract":"<div><h3>Background</h3><div>Pleural carcinosis originates from various cancers. Its management consists in systemic therapies combined to dyspnea relief procedures. Prior studies have tested hyperthermic intrathoracic chemotherapy to treat pleural carcinosis with interesting patient survival results. However, these approaches were limited by local toxicity. Pre-clinical data have shown that hyperthermia combined to local pleural chemotherapy increased the immune response against tumors. Recently, pressurized intraperitoneal aerosol chemotherapies (PIPAC) showed improved cytostatic penetration in abdominal carcinosis with a 10-fold-lower chemotherapy dose and minimal side-effects. This approach was also tested in limited numbers of patients with pleural carcinosis but never combined with hyperthermia.</div></div><div><h3>Methods</h3><div>Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin (PITHAC) is an open-label dose-escalation phase I trial. Patients with pleural carcinosis, eligible for the surgical management of their pleural effusion can be enrolled. Cisplatin (7.5–12–5–35–70 mg/m2) heated at 39±1 °C is delivered into the thoracic cavity before the surgical effusion management. Initially, the study consists in a dose escalation of the four different cisplatin doses. The primary endpoint is the maximal tolerated dose of cisplatin administered by PITHAC. The secondary and translational endpoints are adverse events and the immune response directed against cancer following PITHAC. There is then an expansion phase at the recommended cisplatin dose on an additional 15 patients with identical outcomes.</div></div><div><h3>Discussion</h3><div>Pressurized intrathoracic delivery of chemotherapy under hyperthermic conditions was never tested so far. We plan to determine the safety of such an approach in patients managed for pleural carcinosis. If proven safe, PITHAC could be combined with systemic immunotherapies for the management of cancer.</div></div><div><h3>Trial registration</h3><div>ClinicalTrials.gov Identifier: NCT06281860</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100858"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of aspirin in cancer prevention","authors":"Meng Sun ,&nbsp;Jun Yu ,&nbsp;Jie Wan ,&nbsp;Xiaoyun Dou ,&nbsp;Xiaoying Chen ,&nbsp;Fang Ye","doi":"10.1016/j.ctarc.2025.100884","DOIUrl":"10.1016/j.ctarc.2025.100884","url":null,"abstract":"<div><div>Aspirin [<span><span>1</span></span>], also known as acetylsalicylic acid, is a common non-steroidal anti-inflammatory drug (NSAID). The available evidence shows that aspirin can effectively prevent and treat diseases such as rectal, gastric, ovarian, prostate, and lung cancer. Aspirin has been extensively studied for the prevention and treatment of colorectal cancer. In recent years, studies have found that the potential mechanism of aspirin in the prevention and treatment of cancer may lie in immune regulation, the role of DNA repair pathways, the regulation of cell metabolism, anti-inflammatory effects and antiplatelet effects.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100884"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of immunotherapies in combination with temozolomide as treatment for glioblastoma","authors":"Brendan Chen,&nbsp;Janet Alder","doi":"10.1016/j.ctarc.2025.100888","DOIUrl":"10.1016/j.ctarc.2025.100888","url":null,"abstract":"<div><div>Glioblastomas comprise a significant percentage of malignant adult central nervous system tumor cases and patients typically do not survive longer than a year after diagnosis. There are few treatment options for patients which meaningfully prolong survival other than chemotherapy, radiotherapy, and surgery. There are many clinical trials examining immunotherapy-chemotherapy combination treatments. This systematic review uses database research of clinical trials to identify randomized controlled immunotherapy-temozolomide combination trials which evaluate the median overall and progression-free survival in adult patients. The review also assesses the study design of selected trials for risk of bias. The desired outcomes are presented as they are reported in the selected studies and are evaluated based on reported statistical significance. We included 10 studies in the final selection and found five studies focused on bevacizumab as an immunotherapy in combination with temozolomide while five used unique interventions. Of those studies, only bevacizumab and autologous dendritic cell vaccination reported an improvement in desired outcomes compared to the control. The risk of bias analysis identified only one study with high risk of bias and five studies with unclear risk of bias in blinding. Our study identifies promising treatments and recommends further examination of those interventions but does not make any recommendations on changes to current glioblastoma treatments. The authors have no funding or conflict of interests to declare. The authors followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines for writing this review.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100888"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of Atezolizumab in patients with locally-advanced or metastatic non-small cell lung cancer after prior chemotherapy under real-life conditions in Germany: The Non-interventional Study HYPERION","authors":"Niels Reinmuth ,&nbsp;Christian Geßner ,&nbsp;Thomas Schichtl ,&nbsp;Wolfgang Schütte ,&nbsp;Stefan Hammerschmidt ,&nbsp;Holger Schulz ,&nbsp;Max Zortel ,&nbsp;Ralf Zerbes ,&nbsp;Martin Reck","doi":"10.1016/j.ctarc.2025.100878","DOIUrl":"10.1016/j.ctarc.2025.100878","url":null,"abstract":"<div><h3>Background</h3><div>Atezolizumab is the first approved PD-L1 inhibitor for patients with advanced non-small cell lung cancer (NSCLC) in Germany. This study aimed to assess effectiveness and safety of this checkpoint inhibitor in clinical routine practice. In addition, potential correlating factors between patient or disease characteristics and clinical benefit of atezolizumab were addressed.</div></div><div><h3>Methods</h3><div>HYPERION was a prospective, multicenter, non-interventional, two-cohort study collecting primary data in patients with locally-advanced or metastatic NSCLC after prior chemotherapy treated with atezolizumab.</div><div>Patients were assigned to one of two cohorts depending on their clinical benefit from atezolizumab, i.e., lack of benefit (Cohort 1) or durability of clinical benefit and tumor response (Cohort 2), as assessed by the physicians.</div></div><div><h3>Results</h3><div>Between May 2018 and August 2023, 353 patients were observed, including 179 in Cohort 1 and 174 in Cohort 2. The median age was 68 years and 61 % were men.</div><div>The median time to loss of clinical benefit was 106 days (95 % CI: 93, 119) overall (<em>n</em> = 353 patients) and 256 days (95 % CI: 210, 339) for Cohort 2 (<em>n</em> = 174 patients).</div><div>In total, 243 (68.8 %) patients experienced at least one adverse event (AE) and 146 (41.4 %) patients at least one serious AE.</div><div>A higher proportion of PD-L1 positive patients was observed for Cohort 2 than for Cohort 1.</div></div><div><h3>Conclusion</h3><div>HYPERION confirmed effectiveness of atezolizumab in clinical practice. Results supported a known correlation between PD-L1 expression and a higher benefit of atezolizumab treatment. Atezolizumab treatment was associated with an acceptable safety profile.</div></div><div><h3>Micro abstract</h3><div>The two-cohort non-interventional study HYPERION assessed the effectiveness and safety of atezolizumab in 353 patients with locally-advanced or metastatic NSCLC after prior chemotherapy, depending on lack of benefit (Cohort 1; <em>n</em> = 179) or durability of clinical benefit and tumor response (Cohort 2; <em>n</em> = 174). Atezolizumab showed effectiveness in clinical practice. Results were consistent with the known safety profile.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100878"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The symptom burden of women with a known risk of breast cancer receiving risk reducing medication","authors":"Meagan S. Whisenant, Jessica Treviño Jones, Anneliese O. Gonzalez, Therese Bartholomew Bevers, Kelly Brassil, Darcy Ponce, Sharvari Kamat, Emily Solis, Ann Maliackal, Hannah G. Warlick, Amie Walters, Chloe Denham, Loretta A. Williams","doi":"10.1016/j.ctarc.2023.100784","DOIUrl":"https://doi.org/10.1016/j.ctarc.2023.100784","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"689 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}